Updated results of the INTELLANCE 2/EORTC trial 1410 randomized phase II study on Depatux –M alone, Depatux-M in combination with temozolomide (TMZ) and either TMZ or lomustine (LOM) in recurrent EGFR amplified glioblastoma (NCT02343406).Martin J. van den Bent, Vassilis Golfinopoulos, Anna Maria Elisabeth Walenkamp et al.|Journal of Clinical Oncology|2018Cited by 14
ACTR-39. TWO-YEAR RESULTS OF THE INTELLANCE 2/EORTC TRIAL 1410 RANDOMIZED PHASE II STUDY ON DEPATUX–M ALONE, DEPATUX-M COMBINED WITH TEMOZOLOMIDE (TMZ) AND EITHER TMZ OR LOMUSTINE IN RECURRENT EGFR AMPLIFIED GLIOBLASTOMA (NCT02343406Martin J. van den Bent, Vassilis Golfinopoulos, Pim J. French et al.|Neuro-Oncology|2018Cited by 4